Elagolix
Elagolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist that works by competitively binding to GnRH receptors in the pituitary gland, thereby inhibiting endogenous GnRH signaling and reducing the production of ovarian hormones. When combined with estradiol and norethindrone acetate (as in ORIAHNN), it is used to treat moderate to severe symptoms of uterine fibroids, including heavy menstrual bleeding, in premenopausal women.
A GnRH receptor antagonist used in combination therapy for treating heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- H01CC03
- RxNorm
- 2049846
- Generic
- Elagolix
- Class
- atc-h01
- Brands
- Orilissa
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet, capsule
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Treats moderate to severe symptoms of uterine fibroids, particularly heavy menstrual bleeding, in premenopausal women. Available as combination therapy (elagolix with estradiol/norethindrone acetate) under the brand name ORIAHNN.
Elagolix is a GnRH receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, blocking endogenous GnRH signaling. This leads to decreased secretion of gonadotropins (LH and FSH), which results in reduced ovarian hormone production (estrogen and progesterone).
Should be used at the lowest effective dose and for the shortest duration consistent with treatment goals. May cause decreased bone mineral density with prolonged use; monitoring is recommended. Not recommended for use in women with known liver impairment. Common side effects include hot flashes, headaches, and mood changes. Drug interactions may occur with certain CYP3A4 substrates and inducers. Regular liver function monitoring may be required during treatment.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy